| Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal N Ikenaga, ZW Peng, KA Vaid, SB Liu, S Yoshida, DY Sverdlov, ... Gut 66 (9), 1697-1708, 2017 | 259 | 2017 |
| Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease GA Kwong, G Von Maltzahn, G Murugappan, O Abudayyeh, S Mo, ... Nature biotechnology 31 (1), 63-70, 2013 | 237 | 2013 |
| Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice SB Liu, N Ikenaga, ZW Peng, DY Sverdlov, A Greenstein, V Smith, ... The FASEB Journal 30 (4), 1599-1609, 2016 | 221 | 2016 |
| Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice S Yoshida, N Ikenaga, SB Liu, ZW Peng, J Chung, DY Sverdlov, ... Gastroenterology 147 (6), 1378-1392, 2014 | 155 | 2014 |
| Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation K Kuramitsu, DY Sverdlov, SB Liu, E Csizmadia, L Burkly, D Schuppan, ... The American journal of pathology 183 (1), 182-194, 2013 | 139 | 2013 |
| Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis ZW Peng, N Ikenaga, SB Liu, DY Sverdlov, KA Vaid, R Dixit, PH Weinreb, ... Hepatology 63 (1), 217-232, 2016 | 116 | 2016 |
| A new Mdr2−/− mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer N Ikenaga, SB Liu, DY Sverdlov, S Yoshida, I Nasser, Q Ke, PM Kang, ... The American journal of pathology 185 (2), 325-334, 2015 | 92 | 2015 |
| The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis ZW Peng, S Rothweiler, G Wei, N Ikenaga, SB Liu, DY Sverdlov, KA Vaid, ... Hepatology communications 1 (9), 957-972, 2017 | 34 | 2017 |
| Dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal-regulating kinase 1 (ASK1) potently inhibits fibrosis and portal hypertension in a … N Ikenaga, SB Liu, ZW Peng, AE Greenstein, D French, V Smith, Y Popov Hepatology 62, 881A-881A, 2015 | 6 | 2015 |
| Targeting lysyl oxidase like 2 (LOXL2) inhibits collagen cross-linking and accelerates reversal of pre-established liver fibrosis: 25 N Ikenaga, S Yoshida, SB Liu, J Chung, D Sverdlov, D Marshall, V Barry, ... Hepatology 58, 219A-220A, 2013 | 3 | 2013 |
| Selective inhibition of lysyl oxidase like 2 (LOXL2) using a therapeutic monoclonal antibody suppresses the progression of biliary fibrosis in novel PSC-like mouse model: 788 N Ikenaga, S Yoshida, SB Liu, J Chung, D Sverdlov, D Marshall, V Barry, ... Hepatology 58, 581A-582A, 2013 | 2 | 2013 |
| Selective antibody targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal via crosslinking-dependent and independent … N Ikenaga, SB Liu, ZW Peng, S Yoshida, D Sverdlov, S Karnik, ... Hepatology 62, 886A-886A, 2015 | 1 | 2015 |
| CD39/ENTPD1 is protective in a model of biliary fibrosis and modulates CD8+ T cell gut-homing via alpha 4 beta 7 integrin S Rothweiler, ZW Peng, SB Liu, N Ikenaga, Y Popov, SC Robson HEPATOLOGY 62, 619A-620A, 2015 | | 2015 |
| ENDTP1/CD39 deficiency aggravates liver injury and fibrosis in sclerosing cholangitis model in Mdr2-/-mice: 408 ZW Peng, N Ikenaga, SB Liu, SC Robson, Y Popov Hepatology 60, 402A, 2014 | | 2014 |
| Platelets as a novel target in liver fibrosis: extrahepatic supply of PDGF-B by platelets drives hepatic stellate cell activation and biliary liver fibrosis progression: 778 S Yoshida, N Ikenaga, SB Liu, D Sverdlov, M Shimada, M Tobari, ... Hepatology 60, 576A, 2014 | | 2014 |
| Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits hepatic fibrosis reversal in mice: 768 SB Liu, N Ikenaga, D Sverdlov, ZW Peng, D Schuppan, Y Popov Hepatology 60, 572A, 2014 | | 2014 |
| Hepatocyte-derived mitochondrial DNA acts as a “danger signal” to promote inflammation and fibrosis in non-alcoholic steatohepatitis: 1096 N Ikenaga, M Miyamoto, SB Liu, ZW Peng, S Yoshida, K Khrapko, ... Hepatology 60, 733A-734A, 2014 | | 2014 |
| Novel mouse model of PSC-like liver disease with rapid progression of severe fibrosis, early onset portal hypertension and accelerated tumorigenesis: 776 N Ikenaga, SB Liu, D Sverdlov, Q Ke, PM Kang, Y Popov Hepatology 58, 576A, 2013 | | 2013 |
| 596 TARGETING OF LYSYL OXIDASE-LIKE-2 (LOXL2) PROMOTES REVERSAL OF LIVER FIBROSIS VIA INHIBITION OF COLLAGEN CROSS-LINKING AND FIBROTIC MATRIX STABILIZATION N Ikenaga, S Yoshida, SB Liu, J Chung, D Sverdlov, D Marshall, V Smith, ... Journal of Hepatology 58, S243-S244, 2013 | | 2013 |
| Targeting histone deacetylase (HDAC) using novel selective inhibitors potently attenuates progression of hepatotoxin-induced liver fibrosis in mice: 1206 S Yoshida, SB Liu, J Chung, D Sverdlov, S Karnik, M Sulfab, M Graupe, ... Hepatology 56, 767A-768A, 2012 | | 2012 |
Yury V. PopovAssociate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical SchoolVerified email at bidmc.harvard.edu
